Ghost Tree Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Ghost Tree Capital’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-295,000	Closed	-$7.62M	–	65
2018 Q2	$7.62M	Sell	295,000 -30,000	-9%	-$831K	2.24%	16
2018 Q1	$7.77M	Buy	+325,000	New	+$10.2M	1.57%	21

Other funds holding ADMS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Ghost Tree Capital's ADMS Position: Q3 2018 in Review

Ghost Tree Capital sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 295,000 shares — an estimated $7.62M sold.

Ghost Tree Capital first reported a position in ADMS in Q1 2018 and held it in 2 quarters. The position peaked at $7.77M in Q1 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

Ghost Tree Capital reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Ghost Tree Capital sold 295,000 Adamas Pharmaceuticals shares in Q3 2018, an estimated $7.62M.
Ghost Tree Capital first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 2 quarters.
Ghost Tree Capital's Adamas Pharmaceuticals position peaked at $7.77M in Q1 2018.
125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on Ghost Tree Capital's 13F filing for Q3 2018, filed 14 Nov 2018.